Launch Of Zolvix Revolutionises Sheep Worm Control

< BACK TO RURAL FARMING starstarstarstarstar   Community - Rural Farming Press Release
30th August 2010, 02:37pm - Views: 705





Community Rural Farming Novartis Animal Health 1 image



Novartis Animal Health

Australasia Pty Limited

54 Waterloo Road

North Ryde

NSW 2113














1/2


MEDIA RELEASE  •  COMMUNIQUE AUX MEDIAS  •  MEDIENMITTEILUNG


Launch of ZOLVIX

®

revolutionises sheep worm control



Novartis Animal Health today announced the official Australian launch of

ZOLVIX

®

(monepantel), from the new Orange Drench Class – the first new class

of sheep drench since the 1980s.


To view the Multimedia News Release, please click below:-


af74d65b2da1


Sydney, August, 30, 2010 Novartis Animal Health today announced that on               

1 September 2010 ZOLVIX, a revolutionary sheep drench and the first product from the

new class of anthelmintics called the Amino-Acetonitrile Derivatives (AADs), will be

officially launched in Australia. 


ZOLVIX contains the active ingredient monepantel which has a novel, nematode specific

mode of action. ZOLVIX kills >99.9% of worms, including those resistant to existing

anthelmintic (drench) classes. No ZOLVIX resistant worm populations exist in the field.


Currently available drenches have been a valuable resource in the battle against gastro-

intestinal worms; however, increasingly worms are becoming resistant to these older

treatments, which means their performance is reduced and producers may incur

productivity and financial losses.


Australia is one of the global leaders when it comes to resistance, with sheep drench

resistance present on more than 90% of farms, in many cases to more than one drench

class. 


ZOLVIX is the first truly novel drench for sheep in more than two decades and is the first

from the new AAD or orange drench class. It is highly effective against worms, including

worms whose resistance to existing drenches threatens both the profitability and

sustainability of sheep farming.


Dr. Brown Besier, Principal Veterinary Parasitologist in the Department of Agriculture and

Food Western Australia said, “This new anthelmintic is urgently needed, as drench

resistance affects almost all sheep farms in Australia. The new product will be of major

benefit itself, and will take the pressure off other drench classes as well.”


Dr. Justin Bailey, Technical Services Veterinarian, Novartis Animal Health, supported

these comments, “By integrating ZOLVIX into their drenching program this season sheep

producers will have the peace of mind that they are killing >99.9% of worms regardless of

their drench resistance status. This will maximise the health and productivity of their flock

now and into the future”.


Novartis Animal Health has also launched the Optimum™ drenching system, which

consists of the new, award-winning Optiline

®

drencher and Optivix

®

backpack,

both of

which were created in close cooperation with sheep producers and industry experts. 




2/2

The Optiline drencher has been ergonomically designed to make it easy to use, with the

welfare of both the animal and user in mind. Altogether, the new drenching system is a

ground-breaking step forward in making drenching less of a hassle for sheep producers

and ensuring that the correct dose of ZOLVIX is given to sheep every time.

Rod Walker, Simcro Executive Director said, “Novartis had the vision to insist that a

radical new drench deserved an innovative new drench gun. They also had the courage

and the confidence that Simcro could transform a drench gun concept into a highly

regarded and practical product.  And so the Optiline drencher was born.” 

ZOLVIX will be available from leading rural resellers around Australia from 1 September

2010. For more information on ZOLVIX contact 1800 ZOLVIX (1800 965849) or visit your

rural reseller. 


Disclaimer

This release contains certain forward-looking statements relating to the Group's business, which can be identified by

terminology such as “highly effective”, “unique”, “revolutionise”, “novel”, or similar expressions, or by express or implied

discussions regarding potential new products, potential new indications for existing products, or regarding potential future

revenues from any such products, or potential future sales or earnings of the Novartis Group or any of its divisions or

business units; or by discussions of strategy, plans, expectations or intentions. You should not place undue reliance on

these statements. Such forward-looking statements reflect the current views of the Group regarding future events, and

involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different

from any future results, performance or achievements expressed or implied by such statements. There can be no

guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for

existing products in any market, or that such products will achieve any particular revenue levels. Nor can there be any

guarantee that the Novartis Group, or any of its divisions or business units, will achieve any particular financial results. In

particular, management's expectations could be affected by, among other things, uncertainties involved in the

development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing

clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally;

the Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the

uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing

and other political pressures; the impact that the foregoing factors could have on the values attributed to the Group's

assets and liabilities as recorded in the Group's consolidated balance sheet; and other risks and factors referred to in

Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these

risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from

those described herein as anticipated, believed, estimated or expected. Novartis is providing the information in these

materials as of this date and does not undertake any obligation to update any forward-looking statements as a result of

new information, future events or otherwise.


About Novartis Animal Health 

Novartis Animal Health researches, develops and commercialises leading animal treatments that meet the needs of pet

owners, producers and veterinarians. Headquartered in Basel, Switzerland and present in almost 40 countries, Novartis



About Novartis

Novartis AG provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on

healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic

pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with

leading positions in these areas. In 2008, the Group's continuing operations achieved net sales of USD 41.5 billion and net

income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group.

Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 96,700 full-time-equivalent

associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com


ZOLVIX

®

,Optiline

®

and Optivix

®


are

registered trademarks and OptimumTM

is a trademark of Novartis AG, Basel,

Switzerland. Novartis Animal Health, 54 Waterloo Road, North Ryde NSW 2113.


# # #

Media Contacts:


Justine Mackay, Publicis Life Brands                                                 Sarah Reed, Publicis Life Brands

+612 9006 2944 (direct)                                                                        +612 9006 2940 (direct)

+614 3532 5954 (mobile)                                                                      +614 2132 7366 (mobile)

justine.mackay@publicislifebrands.com.au                                           sarah.reed@publicislifebrands.com.au







news articles logo NEWS ARTICLES
Contact News Articles |Remove this article